The exercise period for Initiator Pharma’s warrants of series TO 2 begins today

Today, the 24th of November 2020, the exercise period for Initiator Pharma A/S (“Initiator” or the “Company”) warrants of series TO 2 that were issued in connection with the Company’s latest rights issue of units and directed issue of units commences. The exercise period runs until the 15th of December 2020. Upon full exercise of warrants, Initiator Pharma will receive approximately SEK 16.4 million before issue costs – capital that will finance the completion of the Company’s clinical phase IIa study. Sedermera Fondkommission is the financial adviser and Markets & Corporate Law Nordic AB is the legal adviser in connection with the warrant exercise.

Teaser

ENG

SWE

 

Anmälningssedel för teckning av aktier med stöd av teckningsoptioner av serie TO 2 i Initiator Pharma A/S

Subscription form for exercising of warrants of series TO 2 in Initiator Pharma A/S